On November 7, 2019, Pfizer Inc., a US pharmaceutical company, stated in a filing with the US Securities and Exchange Commission that in June 2019 it had received an informal request from the FCPA unit of the US Department of Justice, seeking information relating to the Company’s operations in Russia. Pfizer stated that it had received a similar informal request from the SEC’s FCPA unit in September 2019. Pfizer stated that it is producing records pursuant to these requests.
November 7, 2019
US pharmaceutical company under investigation by DOJ, SEC
Related by Topic
New Post
EU Council’s Position on the Omnibus Package: Key Takeaways, Interplay with the Defence Readiness Omnibus Bill, and the Evolving Sustainability Framework
June 30, 2025
Insight
New Post
Rising Cross-Border Enforcement Risk for Companies Operating in Latin America
June 26, 2025
Insight
New Post
The EU Defense Readiness Omnibus Bill: Key Takeaways for Industry Stakeholders and Investors
June 23, 2025
Insight